NERI, ANTONINO
NERI, ANTONINO
Dipartimento di Oncologia ed Emato-Oncologia
Whole-exome sequencing is feasible on a fresh-frozen skin sample of intravascular large B cell lymphoma
2024 F. Bagnoli, G. Pini, B. Ziccheddu, A. Bonometti, S. Alberti-Violetti, L. Venegoni, G. Isimbaldi, M.C. Da Vià, A. Ferrari, L. Baldini, A. Neri, F. Onida, N. Bolli, E. Berti
DIS3 depletion in multiple myeloma causes extensive perturbation in cell cycle progression and centrosome amplification
2023 V.K. Favasuli, D. Ronchetti, I. Silvestris, N. Puccio, G. Fabbiano, V. Traini, K. Todoerti, S. Erratico, A. Ciarrocchi, V. Fragliasso, D. Giannandrea, F. Tumiatti, R. Chiaramonte, Y. Torrente, P. Finelli, E. Morelli, N.C. Munshi, N. Bolli, A. Neri, E. Taìana
Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort
2023 D. Cattaneo, C. Bucelli, A. Marchetti, M. Lionetti, E. Fermo, V. Bellani, C. De Magistris, A. Maeda, A. Marella, M. Primignani, D. Consonni, U. Gianelli, A. Neri, L. Baldini, N. Bolli, A. Iurlo
The Potential of JAG Ligands as Therapeutic Targets and Predictive Biomarkers in Multiple Myeloma
2023 N. Platonova, E. Lazzari, M. Colombo, M. Falleni, D. Tosi, D. Giannandrea, V. Citro, L. Casati, D. Ronchetti, N. Bolli, A. Neri, F. Torricelli, L.A. Crews, C.H.M. Jamieson, R. Chiaramonte
Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins
2023 E. Taiana, C. Bandini, V.K. Favasuli, D. Ronchetti, I. Silvestris, N. Puccio, K. Todoerti, S. Erratico, D. Giannandrea, N. Bolli, N. Amodio, A. Ciarrocchi, R. Chiaramonte, Y. Torrente, R. Piva, A. Neri
Impact on thrombotic risk of canonical and atypical CALR mutations in essential thrombocythemia. A single-center cohort study
2022 S. Fabris, D. Cattaneo, S. Salerio, C. Bucelli, G. Ciceri, R. Pasquale, K. Todoerti, U. Gianelli, L. Baldini, A. Neri, A. Iurlo
Efficacy of front-line ibrutinib and rituximab combination and the impact of treatment discontinuation in unfit patients with chronic lymphocytic leukemia : results of the Gimema LLC1114 Study
2022 F.R. Mauro, F. Paoloni, S. Molica, G. Reda, L. Trentin, P. Sportoletti, M. Marchetti, D. Pietrasanta, R. Marasca, G. Gaidano, M. Coscia, C. Stelitano, D. Mannina, N. Di Renzo, F. Ilariucci, A.M. Liberati, L. Orsucci, F. Re, M. Tani, G. Musuraca, D. Gottardi, P.L. Zinzani, A. Gozzetti, A. Molinari, M. Gentile, A. Chiarenza, L. Laurenti, M. Varettoni, A. Ibatici, R. Murru, V. Ruocco, I. Del Giudice, M.S. De Propris, I. Della Starza, S. Raponi, M. Nanni, P. Fazi, A. Neri, A. Guarini, G.M. Rigolin, A. Piciocchi, A. Cuneo, R. Foà
Single-Cell RNA Sequencing for the Detection of Clonotypic V(D)J Rearrangements in Multiple Myeloma
2022 A. Matera, A. Marella, A. Maeda, M.C. Da Via, F. Lazzaroni, S. Fabris, S. Pioggia, L. Porretti, F. Colombo, F. Torricelli, A. Neri, E. Taiana, G. Fabbiano, V. Traini, E. Genuardi, D. Drandi, N. Bolli, M. Lionetti
Expression levels of NONO, a nuclear protein primarily involved in paraspeckles function, are associated with several deregulated molecular pathways and poor clinical outcome in multiple myeloma
2022 D. Ronchetti, V.K. Favasuli, I. Silvestris, K. Todoerti, F. Torricelli, N. Bolli, A. Ciarrocchi, E. Taiana, A. Neri
Clinical, Morphological and Clonal Progression of VEXAS Syndrome in the Context of Myelodysplasia Treated with Azacytidine
2022 M. Manzoni, A. Bosi, S. Fabris, M. Lionetti, S. Salerio, A.C. Migliorini, F. Cavallaro, K. Barbullushi, N. Rampi, V. Montefusco, M.G. Alessio, A. Neri, L. Baldini, M. Sciumè, E. Tagliaferri, N. Fracchiolla, N. Bolli
Molecular Modelling of NONO and SFPQ Dimerization Process and RNA Recognition Mechanism
2022 T. Laurenzi, L. Palazzolo, E. Taiana, S. Saporiti, O. Ben Mariem, U. Guerrini, A. Neri, I. Eberini
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
2022 A. Bruzzese, D. Derudas, M. Galli, E.A. Martino, S. Rocco, C. Conticello, C. Califano, N. Giuliani, S. Mangiacavalli, G. Farina, A. Lombardo, M. Brunori, E. Rossi, E. Antonioli, R. Ria, R. Zambello, N. Di Renzo, G. Mele, G. Marcacci, G. Pietrantuono, G. Palumbo, N. Cascavilla, C. Cerchione, A. Belotti, C. Criscuolo, G. Uccello, P. Curci, E. Vigna, F. Mendicino, E. Iaccino, S. Mimmi, C. Botta, D. Vincelli, N. Sgherza, A. Bonalumi, L. Cupelli, R. Stocchi, M. Martino, S. Ballanti, D. Gangemi, A. Gagliardi, B. Gamberi, A. Pompa, G. Tripepi, F. Frigeri, U. Consoli, S. Bringhen, E. Zamagni, F. Patriarca, V. De Stefano, F. Di Raimondo, S. Palmieri, M.T. Petrucci, M. Offidani, P. Musto, M. Boccadoro, M. Cavo, A. Neri, F. Morabito, M. Gentile
MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort
2022 M.C. Da Vià, M. Lionetti, A. Marella, A. Matera, E. Travaglino, E. Signaroldi, A.A. Galbussera, U. Lucca, S. Mandelli, E. Riva, M. Tettamanti, L. Pettine, A. Pompa, L. Baldini, A. Neri, M.G. Della Porta, N. Bolli
Validation of the alternative international prognostic score-E (AIPS-E): analysis of binet stage a chronic lymphocytic patients enrolled into the O-CLL1-GISL protocol
2021 F. Morabito, G. Tripepi, E. Vigna, S. Bossio, G. D'Arrigo, E.A. Martino, F. Storino, A.G. Recchia, G. Fronza, F. Di Raimondo, M. Colombo, F. Fais, A. Neri, G. Cutrona, M. Ferrarini, M. Gentile
Genomic instability in multiple myeloma: A “non‐coding rna” perspective
2021 E. Taiana, M.E.G. Cantafio, V.K. Favasuli, C. Bandini, G. Viglietto, R. Piva, A. Neri, N. Amodio
Oleil hydroxytyrosol (Htol) exerts anti-myeloma activity by antagonizing key survival pathways in malignant plasma cells
2021 K. Todoerti, M.E. Gallo Cantafio, M. Oliverio, G. Juli, C. Rocca, R. Citraro, P. Tassone, A. Procopio, G. De Sarro, A. Neri, G. Viglietto, N. Amodio
DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome
2021 K. Todoerti, D. Ronchetti, V. Favasuli, F. Maura, F. Morabito, N. Bolli, E. Taiana, A. Neri
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients
2021 J.C. Reid, D. Golubeva, A.L. Boyd, C.G. Hollands, C. Henly, L. Orlando, A. Leber, J. Hebert, F. Morabito, G. Cutrona, L. Agnelli, M. Gentile, M. Ferrarini, A. Neri, B. Leber, M. Bhatia
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
2021 F. Morabito, G. Tripepi, E.A. Martino, E. Vigna, F. Mendicino, L. Morabito, K. Todoerti, H. Al-Janazreh, G. D'Arrigo, F.A. Canale, G. Cutrona, A. Neri, M. Martino, M. Gentile
Genomics of smoldering multiple myeloma: Time for clinical translation of findings?
2021 M. Lionetti, M.C. Da Via, F. Albano, A. Neri, N. Bolli, P. Musto